Can clinical practice guide a research agenda?

Schizophrenia Bulletin

Volumn 28, Issue 1, 2002, Pages 127-129

  Marder, Stephen R ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic; Clozapine; Evidence based practice; Polypharmacy; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RESEARCH; SCHIZOPHRENIA; SIDE EFFECT; CLASSIFICATION; CLINICAL PATHWAY; DRUG COMBINATION; NOTE; PRACTICE GUIDELINE; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; CRITICAL PATHWAYS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES; RESEARCH; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0035988552     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006915     Document Type: Article

References (7)

1. Comparative efficacy of olanzapine and haloperidol for patients with treatmentresistant schizophrenia
2. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: Implications for State mental health policy
3. Antipsychotic prescribing practices in Connecticut's public mental health system: Rates of changing medications and prescribing styles
4. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders
5. Combination antipsychotics: Pros, cons, and questions
6. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region
7. Risperidone in treatment-refractory schizophrenia